Hans-Jonas Meyer1, Andreas Wienke2, Alexey Surov3. 1. Department of Diagnostic and Interventional Radiology, University of Leipzig, Leipzig, Germany. 2. Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. 3. Department of Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, Germany.
Abstract
Background: Magnetic resonance imaging can be used to diagnose breast cancer (BC). Diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) can be used to reflect tumor microstructure. Objectives: This analysis aimed to compare ADC values between molecular subtypes of BC based on a large sample of patients. Method: The MEDLINE library and Scopus database were screened for the associations between ADC and molecular subtypes of BC up to April 2020. The primary end point of the systematic review was the ADC value in different BC subtypes. Overall, 28 studies were included. Results: The included studies comprised a total of 2,990 tumors. Luminal A type was diagnosed in 865 cases (28.9%), luminal B in 899 (30.1%), human epidermal growth factor receptor (Her2)-enriched in 597 (20.0%), and triple-negative in 629 (21.0%). The mean ADC values of the subtypes were as follows: luminal A: 0.99 × 10-3 mm2/s (95% CI 0.94-1.04), luminal B: 0.97 × 10-3 mm2/s (95% CI 0.89-1.05), Her2-enriched: 1.02 × 10-3 mm2/s (95% CI 0.95-1.08), and triple-negative: 0.99 × 10-3 mm2/s (95% CI 0.91-1.07). Conclusions: ADC values cannot be used to discriminate between molecular subtypes of BC.
Background: Magnetic resonance imaging can be used to diagnose breast cancer (BC). Diffusion-weighted imaging (DWI) and the apparent diffusion coefficient (ADC) can be used to reflect tumor microstructure. Objectives: This analysis aimed to compare ADC values between molecular subtypes of BC based on a large sample of patients. Method: The MEDLINE library and Scopus database were screened for the associations between ADC and molecular subtypes of BC up to April 2020. The primary end point of the systematic review was the ADC value in different BC subtypes. Overall, 28 studies were included. Results: The included studies comprised a total of 2,990 tumors. Luminal A type was diagnosed in 865 cases (28.9%), luminal B in 899 (30.1%), human epidermal growth factor receptor (Her2)-enriched in 597 (20.0%), and triple-negative in 629 (21.0%). The mean ADC values of the subtypes were as follows: luminal A: 0.99 × 10-3 mm2/s (95% CI 0.94-1.04), luminal B: 0.97 × 10-3 mm2/s (95% CI 0.89-1.05), Her2-enriched: 1.02 × 10-3 mm2/s (95% CI 0.95-1.08), and triple-negative: 0.99 × 10-3 mm2/s (95% CI 0.91-1.07). Conclusions: ADC values cannot be used to discriminate between molecular subtypes of BC.
Authors: Mieke Kriege; Cecile T M Brekelmans; Carla Boetes; Peter E Besnard; Harmine M Zonderland; Inge Marie Obdeijn; Radu A Manoliu; Theo Kok; Hans Peterse; Madeleine M A Tilanus-Linthorst; Sara H Muller; Sybren Meijer; Jan C Oosterwijk; Louk V A M Beex; Rob A E M Tollenaar; Harry J de Koning; Emiel J T Rutgers; Jan G M Klijn Journal: N Engl J Med Date: 2004-07-29 Impact factor: 91.245
Authors: Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt Journal: Ann Intern Med Date: 2011-10-18 Impact factor: 25.391
Authors: Javier Zamora; Victor Abraira; Alfonso Muriel; Khalid Khan; Arri Coomarasamy Journal: BMC Med Res Methodol Date: 2006-07-12 Impact factor: 4.615
Authors: André Hennigs; Fabian Riedel; Adam Gondos; Peter Sinn; Peter Schirmacher; Frederik Marmé; Dirk Jäger; Hans-Ulrich Kauczor; Anne Stieber; Katja Lindel; Jürgen Debus; Michael Golatta; Florian Schütz; Christof Sohn; Jörg Heil; Andreas Schneeweiss Journal: BMC Cancer Date: 2016-09-15 Impact factor: 4.430
Authors: Anette Hauge; Catherine S Wegner; Jon-Vidar Gaustad; Trude G Simonsen; Lise Mari K Andersen; Einar K Rofstad Journal: Oncotarget Date: 2017-11-11
Authors: Ashley M Mendez; Lauren K Fang; Claire H Meriwether; Summer J Batasin; Stéphane Loubrie; Ana E Rodríguez-Soto; Rebecca A Rakow-Penner Journal: Front Oncol Date: 2022-07-08 Impact factor: 5.738